Print

Purpose

The purpose of this study is to evaluate how well LY3867070 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Condition

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Are overtly healthy as determined by medical evaluation - Part C of the study includes only Japanese and Chinese participants - Have a body weight greater than or equal to 45 kilogram (kg) and also body mass index 18 to 32 kilogram per square meter (kg/m²) inclusive

Exclusion Criteria

  • Have a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, or history of significant atopy - Have a significant history or current thyroid disease - Have a significant history of or current psychiatric disorders, rheumatologic, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (such as Cushing syndrome and hyperaldosteronism), hematological, or neurological disorders - Are smokers (including electronic cigarettes) within 6 months prior to screening and unwilling to refrain from smoking for the duration of the study. - Unwilling to undergo skin biopsies (for Part B only) - Are unwilling to have body hair cut or shaved in cases where hair, in the investigator's opinion, could interfere with noninvasive skin patch

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Parts A, B, and C are parallel. Part D is open-label fixed-sequence. Part E is crossover.
Primary Purpose
Basic Science
Masking
Double (Participant, Investigator)
Masking Description
Part D will be open-label

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
LY3867070 (Part A) 		Single-Ascending Dose of LY3867070 administered orally
  • Drug: LY3867070
    Administered orally
Experimental
LY3867070 (Part B) 		Multiple-Ascending Doses of LY3867070 administered orally
  • Drug: LY3867070
    Administered orally
Experimental
LY3867070 (Part C) 		Multiple Doses of LY3867070 administered orally
  • Drug: LY3867070
    Administered orally
Placebo Comparator
Placebo (Parts A-C) 		Placebo administered orally
  • Drug: Placebo
    Administered orally
Experimental
LY3867070 (Part D) 		Drug-Drug Interaction (DDI) administered orally
  • Drug: LY3867070
    Administered orally
Experimental
LY3867070 (Optional Part E) 		LY3867070 administered orally
  • Drug: LY3867070
    Administered orally

Recruiting Locations

Fortrea Clinical Research Unit
Dallas 4684888, Texas 4736286 75247
Contact:
469-513-6669

More Details

Status
Recruiting
Sponsor
Eli Lilly and Company

Study Contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.